Candel Therapeutics (NASDAQ:CADL) Stock Price Target Lowered at HC Wainwright

Candel Therapeutics (NASDAQ:CADL) had its price objective decreased by investment analysts at HC Wainwright from $23.00 to $18.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s price objective suggests a potential upside of 183.46% from the company’s previous close.

Several other research analysts also recently issued reports on CADL. UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. Jefferies Financial Group assumed coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Thursday, October 15th. Zacks Research cut Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.57.

Candel Therapeutics Price Performance

Shares of CADL traded down $2.04 during trading hours on Friday, hitting $6.35. The stock had a trading volume of 4,194,395 shares, compared to its average volume of 1,438,046. The company’s fifty day moving average is $9.89 and its two-hundred day moving average is $8.39. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $14.00. The stock has a market capitalization of $485.90 million, a price-to-earnings ratio of -4.49 and a beta of -0.27.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. On average, analysts anticipate that Candel Therapeutics will post -1.29 EPS for the current year.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at approximately $922,380. The trade was a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.30% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds have recently modified their holdings of the business. ACT Capital Partners L.P. bought a new position in shares of Candel Therapeutics during the 3rd quarter valued at about $1,571,000. Russell Investments Group Ltd. increased its position in shares of Candel Therapeutics by 172.6% during the third quarter. Russell Investments Group Ltd. now owns 43,639 shares of the company’s stock worth $456,000 after acquiring an additional 27,632 shares in the last quarter. AlphaCentric Advisors LLC raised its holdings in shares of Candel Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 38,259 shares of the company’s stock worth $399,000 after acquiring an additional 1,576 shares during the period. Alps Advisors Inc. raised its holdings in shares of Candel Therapeutics by 36.4% during the third quarter. Alps Advisors Inc. now owns 101,401 shares of the company’s stock worth $1,059,000 after acquiring an additional 27,038 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Candel Therapeutics during the third quarter worth $41,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Candel Therapeutics News Summary

These are some of the CADL news items that stood out recently:

• Positive Sentiment: Candel reported a third-quarter loss of $0.28 per share, narrower than analysts’ $0.34-per-share estimate. Candel Therapeutics Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Canaccord Genuity and Stifel Nicolaus kept Buy ratings but cut their price targets to $13 and $19, respectively, from $25 and $22. The retained ratings are supportive, while the lower targets reflect more cautious expectations. Canaccord Genuity price-target update Stifel Nicolaus price-target update
• Negative Sentiment: Candel now expects to submit a Biologics License Application for aglatimagene around mid-2027. The later timeline delays a key regulatory milestone and adds uncertainty about when the therapy could reach the market, weighing on the shares. Candel outlines mid-2027 BLA plan

Candel Therapeutics Company Profile

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.